Achieve Life Sciences (ACHV) is a pre-revenue clinical-stage biopharmaceutical company with a single asset, cytisinicline, awaiting FDA approval. Under a liquidation lens as of March 31, 2026, the recovery posture is marginally positive on paper but operationally fragile. Total assets of $33.1M against total liabilities of $22.4M yields book equity of $10.7M. Applying liquidation haircuts, the primary recoverable asset pool consists of cash and cash equivalents ($28.1M at 100%), short-term marketable securities ($1.2M at ~95%), and available-for-sale debt securities ($10.2M amortized cost, $10.2M fair value, at ~95%). Intangible assets ($0.7M net) and goodwill ($1.0M) receive zero recovery. The right-of-use asset ($49K) is negligible. Gross liquidating asset value approximates $38-39M before liabilities. On the liability side, current liabilities of $11.8M include $5.6M of convertible debt classified as current (first tranche conversion or near-term settlement risk) and $2.2M in employee-related accruals. Non-current liabilities of $10.6M include $9.3M of convertible debt (non-current tranche of the New Convertible Term Loan maturing June 2028) and $1.3M contingent consideration liability. Total face-value liabilities of $22.4M subtracted from haircut-adjusted assets yield estimated net liquidation recovery to equity in the range of $16-17M, broadly consistent with the $16.2M CLV/LLV/OLV reported in COMPANY_METADATA. This is a thin cushion against an accumulated deficit of $270.4M and a quarterly cash burn of approximately $6.9M from operations. At the current burn rate, the balance sheet supports roughly 4 quarters of runway without additional financing. Materially, the filing discloses a CRL is expected from the FDA before the June 20, 2026 PDUFA date due to a third-party CMO receiving OAI classification and a warning letter—this extends the cash consumption timeline before any revenue is possible. Additionally, an April 2026 private placement issued warrants covering 49.5M shares at $3.51, not yet settled as equity on the March 31, 2026 balance sheet but creating significant future dilution. The convertible term loan ($15M aggregate principal across two tranches) carries conversion prices of $7.00 and $4.854/share respectively; with the stock trading well below those thresholds, cash repayment on maturity in June 2028 is the operative scenario, which constrains future liquidity. The filing does not separately XBRL-tag the Sopharma supply dispute contingent liability or the Omnicom commercial partnership financial commitment, both discussed in MD&A.
▼ Community Notes